A blog about what is new (and old) in the world of active implantable medical devices 

Facebook Twitter Gplus Flickr LinkedIn YouTube RSS
magnify
formats

Boston Scientific Q1 2012 AIMD Results: CRM Down 10%, Neuromodulation 8% Up

Yesterday Boston Scientific announced financial results for the first quarter ended March 31, 2012.  Sales of Cardiac Rhythm Management devices were $501M vs. $559M for Q1 a year ago, or a decrease of 10%.  Sales of  Neuromodulation devices increased by 8% a year ago from $77M to $84M for Q1.

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on Boston Scientific Q1 2012 AIMD Results: CRM Down 10%, Neuromodulation 8% Up  comments